First, it was valsartan from Zhejiang Huahai Pharmaceuticals Co., of Linhai, China. Then it was losartan made by Hetero Labs Ltd., of Hyderabad, India. And now, low levels of N-nitrosodiethylamine (NDEA), a potential carcinogen, have been found in a third sartan, irbesartan, made by Aurobindo Pharma Ltd., also of Hyderabad. As a result, the European Directorate for the Quality of Medicines & Healthcare has suspended the use of Aurobindo's irbesartan API in EU drugs, and national authorities in the EU are considering whether to recall medicines containing the API that are already on the market.